中金发表报告指,药明康德(02359.HK) 2025年业绩符合该行预期。收入454.56亿元人民币(下同),按年升15.8%,持续经营业务收入按年升21.4%;归母净利润191.51亿元,按年升102.7%,主要受出售部分股权及剥离业务带来的一次性收益影响;经调整净利润149.6亿元,按年升41.3%。主营业务利润率提升明显,主要因持续优化生产工艺和经营效率。公司在手订单饱满,截至2025年末...
Source Link中金发表报告指,药明康德(02359.HK) 2025年业绩符合该行预期。收入454.56亿元人民币(下同),按年升15.8%,持续经营业务收入按年升21.4%;归母净利润191.51亿元,按年升102.7%,主要受出售部分股权及剥离业务带来的一次性收益影响;经调整净利润149.6亿元,按年升41.3%。主营业务利润率提升明显,主要因持续优化生产工艺和经营效率。公司在手订单饱满,截至2025年末...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.